Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
about
Rituximab in renal transplantationAgranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritisAutoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment.Use of monoclonal antibodies in renal transplantation.Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.Fludarabine in Waldenstrom's macroglobulinemia.New developments in the management of Waldenström macroglobulinemiaRituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment.Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab.Targeting developmental pathways in children with cancer: what price success?Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia.Pathophysiologic mechanisms and management of neutropenia associated with large granular lymphocytic leukemia.Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?Late-onset neutropenia following rituximab treatment for rheumatologic conditions.Current and future therapeutic approach for Waldenström's macroglobulinemia.Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis.Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.Hydroxychloroquine-induced agranulocytosis in a patient with long-term rheumatoid arthritis.Late-onset neutropenia after rituximab in ANCA-associated vasculitis.Cyclophosphamide-refractory scleroderma-associated interstitial lung disease: remarkable clinical and radiological response to a single course of rituximab combined with high-dose corticosteroids.Incidence of late onset neutropenia associated with rituximab use in B cell lymphoma patients undergoing autologous stem cell transplantation.Biologics in dermatology: adverse effects.Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety.Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis?Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses.Re-challenge with etanercept in patients with etanercept-induced neutropenia.Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma.Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma.Prolonged immunochemotherapy with rituximab, cytarabine and fludarabine added to cyclophosphamide, doxorubicin, vincristine and prednisolone and followed by rituximab maintenance in untreated elderly patients with mantle cell lymphoma: a prospectiveHypogammaglobulinemia Observed One Year after Rituximab Treatment for Idiopathic Thrombocytopenic Purpura.A case of Alemtuzumab-induced neutropenia in multiple sclerosis in association with the expansion of large granular lymphocytesDrug-Induced Hematological Cytopenia in Kidney Transplantation and the Challenges It Poses for Kidney Transplant Physicians
P2860
Q27026434-365F8927-07C2-41BC-A54E-51D9B53CC019Q28071389-01C80A4F-FECD-4B6B-BEB4-ABF27B799008Q33395141-BFDADEA2-A268-478D-B4EE-8922C413BCCDQ33396236-2509B714-1F06-495F-9557-1528FE937585Q33426511-877BBA6A-89F2-4A82-9414-0EB7B0B98ABFQ33895391-92542848-D1EB-427A-BB89-1F1A5B9B6F7CQ33971785-68826557-F2B7-4233-925B-C15A6470136EQ34351916-65F26925-8689-4579-B8D4-D6A06D12F2CCQ34553880-37DE68EB-4FC4-4E0D-9B6E-5E1D34236D0DQ35531665-D6C682D8-1EEC-49BD-AD6A-F0BA6F3F0BCFQ35571040-6FE52B6E-834E-4F5F-9647-8BED2BDB1181Q36264895-DEC98BDB-CFB6-4F9D-87DA-88F4505D5377Q36696574-4980C12D-7CE0-4106-8184-EB1EC557D0CBQ36905620-E4674E91-A05C-458D-BAB6-09B8D87C3895Q37180805-5305C13C-8D26-45CF-B0B2-085C3356DF49Q37462856-6D683FBC-450A-4DF8-8EA3-6593FF8ABB32Q37888717-B72858E4-A065-4192-B315-A0B2CBE09206Q37919869-2DCF08E4-C80A-44A0-82F0-0529DEF0F206Q38193735-7776322C-FA6A-4E0C-8FA7-22196BF46CEEQ38206820-EB0D1304-BE14-46F6-8181-B8E660A04A6FQ38207970-C889E777-7037-4968-8ACF-3633CA42E83DQ38316279-394BEEF2-F4BF-4E32-A968-A6E40A4F6787Q38689784-199E2A92-00CC-44A8-8074-29C814EDB2DCQ38973265-0B0D31D5-ECFA-4A87-AAE2-49DCD5C1C412Q39944154-0AC02CAF-0895-4270-91CD-28560845DDA0Q39983690-129BED47-A421-4D9C-92B9-9047C0FFB890Q40272339-3E68F351-6D9B-427B-B97C-60B5531FF358Q41120913-396A84B5-0FEF-400C-BA7A-C4215D663BFFQ41527816-EF17353F-70E3-48C4-A385-21BAD7711DA9Q42229459-E011D1E5-80B7-4110-ADA2-D8ACF2BFCB08Q42908395-7BD81541-2E6A-4691-A08B-D61F7D5EBAB1Q44586802-7A34F4F8-2A86-4124-A74E-3849C184E00CQ47105115-046EAD60-F05E-4CCE-AD54-40B7286DE02CQ47168459-6D4EB3E1-B6D5-4256-9A90-6120F9DE5C66Q51119875-89217389-3B2C-4F9C-95EB-59AC8B1B46CBQ53134173-443485AD-1A3A-461C-9A03-8240B0CFA9EEQ55233939-BB48C9A4-EF76-43DB-A5D0-E320F0C9EFA6Q58101281-E593389E-DD14-45CF-8EAE-198162A834A2Q58805821-BF72C3D2-E002-41D1-A5C0-90CBF79652E5
P2860
Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Late-onset neutropenia after r ...... sive review of the literature.
@en
Late-onset neutropenia after r ...... sive review of the literature.
@nl
type
label
Late-onset neutropenia after r ...... sive review of the literature.
@en
Late-onset neutropenia after r ...... sive review of the literature.
@nl
prefLabel
Late-onset neutropenia after r ...... sive review of the literature.
@en
Late-onset neutropenia after r ...... sive review of the literature.
@nl
P2093
P1433
P1476
Late-onset neutropenia after r ...... sive review of the literature.
@en
P2093
Meir Lahav
Ofir Wolach
Osnat Bairey
P304
P356
10.1097/MD.0B013E3181F2CAEF
P407
P577
2010-09-01T00:00:00Z